Business
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Canada ...
About this update from Cybin, Inc.
[{"type":"text","content":"\n\n\nPsychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\nIssued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ: HELP), AtaiBeckley (NASDAQ: ATAI), Definium Therapeutics (NASDAQ: DFTX), GH Research (NASDAQ: GHRS), and LB Pharmaceuticals (NASDAQ: LBRX).\n\n\n\n\n\n\n\nA consensus statement from the U.S. National Network of Depression Centers published in The Lancet outlined considerations for integrating psychedelic into routine clinical practice, a signal that academic medicine is preparing for what the trials may deliver[3]. The clinical infrastructure is expanding, and the investment thesis is following.Helus Pharma (NASDAQ: HELP) is a clinical-stage pharmaceutical company developing treatments for depression and anxiety. Its approach centers on novel serotonergic agonists, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.Originally founded as Cybin in 2019, the company rebranded to Helus Pharma in January 2026, pronounced \"Heal-Us,\" and began trading on the NASDAQ under the ticker HELP. The name reflects its transition toward a commercial-ready pharmaceutical operation.The company holds over 350 filed patents with more than 100 already granted, providing protection around its lead programs through at least 2041. It operates across Canada, the United States, the United Kingdom, and Ireland.Recently, Nature Medicine published results from a randomized, placebo-controlled Phase 2a trial of SPL026 in patients with moderate-to-severe major depressive diso...